Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations [Yahoo! Finance]
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
Rallybio Co. (NASDAQ: RLYB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates